DepoMed, Inc. (NASDAQ:DEPO)

CAPS Rating: 4 out of 5

A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.

Recs

0
Player Avatar HealthcareGuy (98.87) Submitted: 9/14/2011 10:32:30 AM : Outperform Start Price: $6.37 DEPO Score: -26.28

Significant insider buying ahead of Serada data, and Gralise launch

Featured Broker Partners


Advertisement